MoonLake Immunotherapeutics (MLTX) Change in Receivables (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) recorded quarterly Change in Receivables of $894000.0 in Q1 2026, up 5.55% quarter-over-quarter from $847000.0 in Q4 2025, and up 512.33% on a YoY basis from $146000.0 in Q1 2025.
MoonLake Immunotherapeutics (MLTX) Change in Receivables (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Change in Receivables history runs 6 years deep, the most recent figure standing at $894000.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 512.33% year-over-year to $894000.0; the TTM figure through Mar 2026 stood at $2.8 million (up 85.73% YoY), while the FY2025 annual figure was $2.0 million, up 13.38% from the prior year.
- Change in Receivables was $894000.0 for Q1 2026 at MoonLake Immunotherapeutics, up from $847000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $894000.0 in Q1 2026 to a low of -$383407.0 in Q4 2022.
- Historically, Change in Receivables has averaged $330197.4 across 5 years, with a median of $336374.0 in 2023.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables slumped 357.71% in 2022, then soared 1083.98% in 2023.
- A 5-year view of Change in Receivables shows it stood at -$383407.0 in 2022, then jumped by 187.73% to $336374.0 in 2023, then climbed by 29.62% to $436000.0 in 2024, then jumped by 94.27% to $847000.0 in 2025, then rose by 5.55% to $894000.0 in 2026.
- The last three Change in Receivables figures came in at $894000.0 (Q1 2026), $847000.0 (Q4 2025), and $612000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -4.08 Mn |
| 10 | MoonLake Immunotherapeutics | 1.25 Bn | 888.66 Mn | - | 894,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 894,000.00 |
| Mar 31, 2026 | 894,000.00 |
| Dec 31, 2025 | 847,000.00 |
| Dec 31, 2025 | 847,000.00 |
| Sep 30, 2025 | 612,000.00 |
| Sep 30, 2025 | 612,000.00 |
| Jun 30, 2025 | 420,000.00 |
| Jun 30, 2025 | 420,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Mar 31, 2025 | 146,000.00 |
| Dec 31, 2024 | 436,000.00 |
| Dec 31, 2024 | 436,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Sep 30, 2024 | 730,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Jun 30, 2024 | 181,000.00 |
| Mar 31, 2024 | 439,000.00 |
| Mar 31, 2024 | 439,000.00 |
| Dec 31, 2023 | 336,374.00 |
| Dec 31, 2023 | 336,374.00 |